U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H27N5O
Molecular Weight 461.5576
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMG-548

SMILES

CN1C(=O)C(C2=CC=C3C=CC=CC3=C2)=C(N=C1NC[C@@H](N)CC4=CC=CC=C4)C5=CC=NC=C5

InChI

InChIKey=RQVKVJIRFKVPBF-VWLOTQADSA-N
InChI=1S/C29H27N5O/c1-34-28(35)26(24-12-11-21-9-5-6-10-23(21)18-24)27(22-13-15-31-16-14-22)33-29(34)32-19-25(30)17-20-7-3-2-4-8-20/h2-16,18,25H,17,19,30H2,1H3,(H,32,33)/t25-/m0/s1

HIDE SMILES / InChI

Description

AMG-548 is a selective and efficacious p38alpha inhibitor (Ki value is 0.5nM). Displays >1000-fold selectivity against 36 other kinases; inhibits whole blood LPS-stimulated TNFα (IC50 = 3 nM). Efficacious in acute and chronic models of arthritis. Clinical development of AMG-548 was terminated because of liver toxicity.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
35.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The dose of AMG-548 can be from 0.1 mg to 1000 mg/day, preferably between 1 and 500 mg/day by oral administration.
Route of Administration: Oral
In Vitro Use Guide
AMG-548 inhibited the Wnt-3a-induced hDvl2 mobility shift in U2OS-EFC cells at 10 uM